Seattle life science funding expected to be big in 2021
Washington’s life science sector is looking to build upon 2020’s record funding as the industry continues to provide critical research and treatments to combat the COVID-19 pandemic. Seattle-based Sana Biotechnology has already led the charge, filing for an IPO in early January.
“All signs point to another banner year in life science investing, particularly in areas of scientific research in which our region excels,” said Leslie Alexandre, president and CEO of Life Science Washington. “COVID-19 has been our industry’s moon- shot moment, bringing attention to the power of science and engineering and I believe motivating a new generation of life scientists (not to mention public health professionals).”